Effect of bromocriptine administration on gastric acid and gastrin secretion in man

Journal of Endocrinological Investigation
R CaldaraA Paracchi

Abstract

The effects of acute oral administration of the dopaminergic drug, bromocriptin (5 mg), on basal and submaximal (1 and 3 microgram per kg bw given sc) and maximal (6 mug per kg bw) pentagastrin-stimulated gastric acid secretion and on basal and meal-induced gastrin release have been evaluated in healthy volunteers. Although basal and maximal pentagastrin-stimulated acid output did not change, the response to submaximal pentagastrin doses was significantly increased. Basal and stimulated serum gastrin concentrations were not modified, nor was fasting serum gastrin during chronic bromocriptine treatment (10 mg per day for 90 days) in acromegalic patients. As dopamine infusion is known to reduce basal and pentagastrin-induced gastric acid secretion, the presently reported effect of bromocriptine is not dependent on dopamine receptor stimulation. It is suggested that it might be due to alpha-adrenergic and/or serotoninergic antagonism, both actions being properties of bromocriptine. Alternatively, since bromocriptine, at variance with iv infused dopamine, crosses the blood-brain barrier, the effect of this drug on gastric function might depend on interference by centrally mediated actions on those directly exerted at the gastric le...Continue Reading

References

Dec 13, 1975·Lancet·Y SachdevS K Goolamali
Oct 16, 1976·Lancet·J A WassP G Chiodini
Feb 19, 1977·Lancet·G O Cowan
Aug 26, 1977·Brain Research·J N DavisR J Leefkowitz
Mar 1, 1977·Pharmacological Research Communications·A J PuechJ R Boissier
Nov 1, 1976·Clinical Endocrinology·B H HirstL A Labib
May 1, 1973·The Journal of Pharmacy and Pharmacology·H CorrodiU Ungerstedt
Sep 16, 1967·Lancet·D Johnston, K Jepson
Nov 23, 1974·British Medical Journal·D B CalneA Petrie
Dec 1, 1972·Scandinavian Journal of Clinical and Laboratory Investigation·F Stadil, J F Rehfeld
Jan 1, 1972·Scandinavian Journal of Gastroenterology·S Aune, J O Stadaas
Dec 1, 1971·The American Journal of Physiology·W H Oldendorf

❮ Previous
Next ❯

Citations

Jan 1, 1983·European Journal of Clinical Pharmacology·R CaldaraC Barbieri
May 1, 1984·British Journal of Clinical Pharmacology·E MasciA Tittobello
Jan 1, 1980·Scandinavian Journal of Gastroenterology·R CaldaraM Romussi
Sep 1, 1990·Digestive Diseases and Sciences·G B Glavin, S Szabo
Apr 1, 1989·Digestive Diseases and Sciences·D E HernandezG A Mason

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.